Clinical experience with the micronucleus assay.
Because of the logistical and practical problems that make cancer prevention trials using cancer incidence as an endpoint virtually impossible to conduct for the majority of cancer types, there is a desperate need for valid intermediate markers of cancer risk to serve as surrogate endpoints in chemoprevention trials. A long and continually growing list of potential markers has been developed in the recent past. Unfortunately very few, if any, of them have been subjected to the usual quality control requirements for a laboratory test before being applied to clinical settings. Modulation of micronuclei frequency has been reported in a number of chemoprevention trials involving the oral cavity, esophagus, lung, and lower GI tract; however, we have focused our efforts primarily on applying the assay to exfoliated buccal mucosal cells, since much of the published data deal with this site, and oral cancer prevention is the theme of one of our chemoprevention trials. After standardizing the definition of a micronucleus by literature review and direct exchange of slides and photographs with other investigators active in the field, we obtained smears from normal subjects, smokers with or without leukoplakia, and tobacco chewers with or without leukoplakia. Our summarized findings follow: (1) Micronuclei represent only one of numerous cytological abnormalities in exfoliated buccal cells that are manifest particularly in tobacco chewers. These include a high frequency of anucleate, binucleate, and multinucleated cells, abnormal shapes and sizes of nuclei, etc.(ABSTRACT TRUNCATED AT 250 WORDS)
Garewal
H S
HS
Arizona Cancer Center, VA Medical Center, Tucson 85723.
Ramsey
L
L
Kaugars
G
G
Boyle
J
J
D016588:Anticarcinogenic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D002986:Clinical Trials as Topic; D006801:Humans; D015162:Micronucleus Tests
D016588:Anticarcinogenic Agents; D014408:Biomarkers, Tumor